Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

Standard Dose
4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER is listed in Drugs@FDA under application 020147 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE Form and strength INJECTABLE;INJECTION - 4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML Sponsor BAXTER HLTHCARE Submission history Latest submission status date: 2001-08-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER is listed in Drugs@FDA under application 020147 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE Form and strength INJECTABLE;INJECTION - 4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML Sponsor BAXTER HLTHCARE Submission history Latest submission status date: 2001-08-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.